Skip to content
10-Q

Quarterly Report

Edgewise Therapeutics, Inc. EWTX

0001104659-26-056713

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 107.59M sh
Shares Diluted Q1 2026 · Mar 31, 2026 107.12M sh
Shares Diluted Q1 2026 · Mar 31, 2025 95.13M sh
Capex Q1 2026 · Mar 31, 2026 $260K
Capex Q1 2026 · Mar 31, 2025 $44K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$42.54M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$37.87M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $33.21M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $61.15M
Stockholders Equity Q1 2026 · Mar 31, 2026 $493.2M
Stockholders Equity Q1 2026 · Dec 31, 2025 $522.26M
Stockholders Equity Q1 2026 · Mar 31, 2025 $429.72M
Stockholders Equity Q1 2026 · Dec 31, 2024 $459.22M
Current Liabilities Q1 2026 · Mar 31, 2026 $22.54M
Current Liabilities Q1 2026 · Dec 31, 2025 $27.37M
Total Liabilities Q1 2026 · Mar 31, 2026 $25.32M
Total Liabilities Q1 2026 · Dec 31, 2025 $30.35M
Current Assets Q1 2026 · Mar 31, 2026 $509.79M
Current Assets Q1 2026 · Dec 31, 2025 $543.39M
Total Assets Q1 2026 · Mar 31, 2026 $518.52M
Total Assets Q1 2026 · Dec 31, 2025 $552.6M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.46
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.43
Eps Basic Q1 2026 · Mar 31, 2026 −$0.46
Eps Basic Q1 2026 · Mar 31, 2025 −$0.43
Sga Expense Q1 2026 · Mar 31, 2026 $11.46M
Sga Expense Q1 2026 · Mar 31, 2025 $9.2M
Rd Expense Q1 2026 · Mar 31, 2026 $42.65M
Rd Expense Q1 2026 · Mar 31, 2025 $36.76M
Net Income Q1 2026 · Mar 31, 2026 −$49.01M
Net Income Q1 2026 · Mar 31, 2025 −$40.8M
Operating Income Q1 2026 · Mar 31, 2026 −$54.12M
Operating Income Q1 2026 · Mar 31, 2025 −$45.96M
Stock Issued Q1 2026 · Apr 3, 2025 9.94M sh